Increased Replication Stress Determines ATR Inhibitor Sensitivity in Neuroblastoma Cells
Authors:
- David KingDKDavid King
- Harriet E. D. SouthgateHSHarriet E. D. Southgate
- Saskia RoetschkeSRSaskia Roetschke
- Polly GravellsPGPolly Gravells
- Leona FieldsLFLeona Fields
- Jessica B. WatsonJWJessica B. Watson
- Lindi ChenLCLindi Chen
- Devon ChapmanDCDevon Chapman
- Daniel HarrisonDHDaniel Harrison
- Daniel YeomansonDYDaniel Yeomanson
- Nicola J. CurtinNCNicola J. Curtin
- Deborah A. TweddleDTDeborah A. Tweddle
Open Access
Abstract
Despite intensive high-dose multimodal therapy, high-risk neuroblastoma (NB) confers a less than 50% survival rate. This study investigates the role of replication stress in sensitivity to inhibition of Ataxia telangiectasia and Rad3-related (ATR) in pre-clinical models of high-risk NB. Amplification of the oncogene MYCN always imparts high-risk disease and occurs in 25% of all NB. Here, we show that MYCN-induced replication stress directly increases sensitivity to the ATR inhibitors VE-821 and AZD6738. PARP inhibition with Olaparib also results in replication stress and ATR activation, and sensitises NB cells to ATR inhibition independently of MYCN status, with synergistic levels of cell death seen in MYCN expressing ATR- and PARP-inhibited cells. Mechanistically, we demonstrate that ATR inhibition increases the number of persistent stalled and collapsed replication forks, exacerbating replication stress. It also abrogates S and G2 cell cycle checkpoints leading to death during mitosis in cells treated with an ATR inhibitor combined with PARP inhibition. In summary, increased replication stress through high MYCN expression, PARP inhibition or chemotherapeutic agents results in sensitivity to ATR inhibition. Our findings provide a mechanistic rationale for the inclusion of ATR and PARP inhibitors as a potential treatment strategy for high-risk NB.Keywords
Funding Information
- CHILDREN with CANCER UK (16 – 217)
- Children's Cancer and Leukaemia Group and Little Princess Trust (CCLGA-2017-12)
- Wellcome (WT093134AIA)
- Medical Research Council (MR/K015753/1)
This publication has 42 references indexed in Scilit:
- RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastomaProceedings of the National Academy of Sciences, 2011
- Recent Advances in NeuroblastomaNew England Journal of Medicine, 2010
- Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and RepairMolecular Cell, 2010
- PARP is activated at stalled forks to mediate Mre11‐dependent replication restart and recombinationThe EMBO Journal, 2009
- Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood NeuroblastomaClinical Cancer Research, 2009
- The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force ReportJournal of Clinical Oncology, 2009
- Myc’s broad reachGenes & Development, 2008
- ATR: an essential regulator of genome integrityNature Reviews Molecular Cell Biology, 2008
- Association of Multiple Copies of the N-mycOncogene with Rapid Progression of NeuroblastomasNew England Journal of Medicine, 1985
- Amplification of N- myc in Untreated Human Neuroblastomas Correlates with Advanced Disease StageScience, 1984